This page is a brief summary only. For complete rules and final terms, please refer to the PDF.
Submission Period
1 April 2026 – 16 May 2026 (JST, UTC+9)
Deadline
16 May 2026, 23:59 (JST)
Late submissions will not be accepted, including those affected by different time zones or technical issues.
Language
English only
Length
Abstract body up to 300 words
Title line, author names, affiliations, and keywords are excluded from the word count.
Structured headings (required)
Background / Methods / Results / Conclusions
Abstracts without Results (e.g., “results will be presented”) may be rejected.
図表
Not allowed
キーワード
3–5
Define abbreviations at first use. Where possible, avoid product trade names and use generic names.
Traffic injury epidemiology / Prevention
Emergency care / Trauma systems
Rehabilitation / Disability after traffic injury
Older drivers / Vulnerable road users
Biomechanics / CAE
Human factors / Psychology
Alcohol, drugs, medical conditions and driving
Road safety policy / Systems / Education
Automated driving / ITS / New mobility
Forensic traffic medicine
Others related to traffic medicine
提出先
contact@itma27-jcts62.jp
Email to
required
ITMA27 Abstract Submission – [Presenting Author Family Name]
Attachment
one file
Format
.docx (preferred) or .pdf
File name
ITMA27_Abstract_[PresentingAuthorFamilyName]_[FirstKeywordOrShortTitle].docx
(Use .pdf if submitting a PDF.)
Required items in the email body
required
●The Secretariat will send an acknowledgement email and issue an Abstract ID within one week after receipt.
If you do not receive an acknowledgement within 7 days, please contact the Secretariat.
●Revisions are allowed before the deadline: resend with subject ITMA27 Abstract Revision – [Abstract ID] and state “Revised version” with the revision date in the email body.
●Abstracts will be reviewed by the Scientific Committee.
●Acceptance/rejection and Oral/Poster assignment are at the discretion of the congress.
●Presentation preference may be indicated; however, the final assignment will be determined by the congress.
Ethics & privacy
Authors are responsible for ethics approval/informed consent where applicable and for anonymizing any personal/patient-identifying information. Do not include identifiers in the abstract.
COI
For accepted presentations (Oral/Poster), a COI disclosure slide is mandatory and must be the first slide.
Rights
Copyright remains with the author(s). The organizers receive a non-exclusive license to reproduce and distribute abstracts in congress abstract materials for registered participants only. Abstract materials will not be publicly available in principle.
This page is a brief summary only. For complete rules and final terms, please refer to the PDF.
